CAR-T cell therapy trials in China

CAR-T (chimeric antigen receptor T-cell) therapy re-engineers a patient's own immune cells to hunt cancer. China runs one of the largest CAR-T trial pipelines in the world, spanning multiple myeloma, lymphoma, leukemia, and a fast-growing set of solid-tumor programs.

For many international patients, a trial is a route to next-generation therapy that isn't yet approved — or is far more costly — at home. Enrollment in the investigational therapy is typically free; patients generally cover travel, lodging, and some routine care. Below are trials currently recruiting, pulled live from the public ClinicalTrials.gov registry.